Bradley Anderson
Analyst · Thinkequity
Thanks, Fokko. Let's review our second quarter results. Net revenue for the second quarter of fiscal 2012 was $21.6 million, down 13% sequentially from $24.7 million for the preceding quarter, and down 65% from the second quarter of fiscal 2011. The decrease was in line with our expectations and was driven by lower system shipments to customers in the solar industry. We were encouraged by our semiconductor revenue for the quarter which totaled $11 million, a 36% increase from last year's quarter and a 21% increase sequentially.
Total orders in the second quarter of fiscal 2012 were $18 million, $7.2 million of which were Solar. This is up 62% compared to total orders of $11.1 million in the preceding quarter. At March 31, 2012, our order backlog was $67.4 million compared to total backlog of $69.2 million at December 31, 2011. Total backlog at March 31, 2012, was $54 million compared to a Solar backlog of $55.8 million at December 31, 2011.
The effect of foreign exchange on backlog was a positive $1.8 million in the March quarter. Backlog includes deferred revenue and customer orders that are expected to shift within the next 12 months.
Gross margin in the second quarter of fiscal 2012 was 19% compared to 29% sequentially, and 40% in the second quarter of fiscal 2011. The lower gross margin is primarily due to lower sales volumes resulting in less-efficient capacity utilization and the write-down of inventory. Also, our net recognition of previously-deferred revenue was lower in the second quarter compared to the first quarter.
Looking at our SG&A expenses. In the first quarter of fiscal 2012 were $6 million -- in this quarter, $6 million, compared to $6.3 million in the preceding quarter, and $11.2 million the second quarter one year ago. The decrease in our SG&A expense as compared to the second quarter of fiscal 2011 was primarily due to lower commissions and shipping costs associated with lower volumes and also reflected corporate-wide cost control initiatives. We recorded an impairment charge of $688,000 in the second quarter due to the write-down of certain licenses and related assets associated with our PSG removal tool, and our previous in-line PECVD tool.
R&D expense was $3.3 million in the second quarter of fiscal 2012 compared to $2.8 million in the preceding quarter and $900,000 in the second quarter of fiscal 2011. The year-over-year quarterly change is primarily due to investment in our solar ion implant project and development costs associated with other products and technology development programs, of which Fokko spoke to.
Depreciation and amortization in the second quarter of fiscal 2012 was $760,000 compared to $769,000 in the first quarter of fiscal 2012. Included in the second quarter of fiscal 2012 results is $437,000 of stock option expense, compared to $369,000 in the second quarter a year ago, and $465,000 in the first quarter of fiscal 2012.
The income tax benefit in the second quarter of fiscal 2012 was $220,000, resulting in an effective tax rate of approximately 4%. The net loss for the second quarter of fiscal 2012 was $5.1 million or a loss of $0.54 per share, compared to net loss of $900,000 or $0.09 per diluted share in the preceding quarter.
Total revenue by geographic region for the fiscal second quarter was in the Asia-Pacific region at 70%, Europe at 23% and North America at 7%. We continue to maintain a solid financial position with essentially no debt and total cash and cash equivalents of $48.8 million at March 31, 2012, compared to $54.9 million at December 31, 2011. The decrease in cash is primarily due to payments to vendors and excess receipts from our customers.
At March 31, 2012, we had working capital of approximately $86.4 million. We will continue to manage operations to maintain our solid financial position. We continue to be focused on reducing our purchase commitments and managing inventory to an appropriate level. During the first 6 months of our fiscal year, we have reduced our purchase commitments by over $24 million.
Now, let me turn to our outlook. The supply demand and balance for solar cells and modules continue to negatively impact the entire solar value chain. As a result, the company expects revenues in its fiscal 2012 third quarter ending June 30, 2012, to be in the range of $18 million to $20 million. Gross margins are expected to be in line with or slightly higher than the second quarter of fiscal 2012. Research and development expenses are expected to be significantly higher in the June quarter compared to the March quarter, primarily due to the bill as a beta version of our solar ion implant system. As a result, Amtech expects to incur a net loss in the third quarter.
As a reminder, our operating results could be impacted by the timing of system shipments, the net impact of revenue deferral on those shipments and the recognition of revenue based on customer acceptances, all of which, have in the past and can in the future, have a significant effect on operating results. In addition, a substantial portion of our revenues is denominated in euros. The revenue outlook we have provided is based on an assumed exchange rate between United States dollar and the euro. A significant decrease in the value of the euro in relation to the U.S. dollar could cause our actual revenues to be lower than anticipated.
This concludes the prepared remarks section of our conference call. Operator, please open the call to questions.